初回治療に bezafibrate の単独投与が有効であった原発性硬化性胆管炎の1例 Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis : A case report

この論文にアクセスする

この論文をさがす

著者

抄録

症例は58歳,女性.生来健康であったが健診にて肝胆道系酵素の上昇を指摘され受診.精査を行い,血清IgG4は正常,ERCP·MRCPにて胆管の帯状狭窄(band-like stricture)や数珠様所見(beaded appearance)を認め原発性硬化性胆管炎(PSC)と診断した.同時に高脂血症もみられたため初回治療としてbezafibrate 400mg/dayの経口単独投与を行いトランスアミナーゼ,ALP,GGTのすみやかな低下を認めた.PSCにbezafibrateの初回単独投与も有効な治療法である可能性が示唆された.<br>

The patient was a 58-year-old female. Though she had been in good healthC increased hepatobiliary enzymes were detected in a health examination. She visited our hospital for close examination. The serum IgG4 level was normal, but ERCP and MRCP showed band-like stricture and beaded appearance of the bile ducts. A diagnosis of primary sclerosing cholangitis (PSC) was made. Since hyperlipidemia was also observedC oral administration of bezafibrate (400mg/day) alone was performed as the initial treatment, and transaminase, ALP, and GGT rapidly decreased. These results suggested that the initial administration of bezafibrate alone is effective against PSC.<br>

収録刊行物

  • 日本消化器病學會雜誌 = The Japanese journal of gastro-enterology  

    日本消化器病學會雜誌 = The Japanese journal of gastro-enterology 103(6), 643-649, 2006-06-05 

    The Japanese Society of Gastroenterology

参考文献:  17件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018364835
  • NII書誌ID(NCID)
    AN00192124
  • 本文言語コード
    JPN
  • 資料種別
    NOT
  • ISSN
    04466586
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ